Overview

HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

Status:
Terminated

Trial end date:
2004-02-01

Target enrollment:

Participant gender:

Summary

HIV-specific immune responses are preserved in patients treated early during primary infection.The trial evaluated whether the addition to HAART of IL-2 alone or combined with an immunization procedure might enhance HIV immune responses and improve viral control after HAART discontinuation

Phase:

Phase 2

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborator:

Aventis Pharmaceuticals